The pharmaceutical industry is characterised by a diversity of products and processes, which vary by plant, time and even season to fulfill the demands of drug production and R&D.
As a result, pharmaceutical wastewater contains various kinds of organic micro-pollutants such as problem organics pollutants (POPs), endocrine disrupting compounds (EDCs) and pharmaceutical and personal care products (PPCPs) that exhibit resistance against biodegradation. Many PPCPs and EDCs are ubiquitous in wastewater at ppb concentration.
The regulators at federal, state, and local level in many parts of the world are responding to rapidly rising public awareness about environmental/laboratory studies showing detrimental effects on aquatic species and possibly on human health and development due the presence of problem micro-pollutants at trace level in treated wastewater.
In many cases, existing wastewater treatment trains need upgrading to combine more than one tertiary wastewater treatment technology to effectively remove all of the micro-pollutants.
Arvia’s Organics Destruction Cell (ODC) Systems enable the design of an effective and optimal advanced or tertiary wastewater treatment process to treat problem pollutants and reduce recalcitrant COD ensuring your wastewater meets GMP requirements and regulatory discharge limits.
The Arvia ODC systems are modular hence can be scaled to handle different flowrate. It is environmentally friendly since no chemicals are required and no secondary waste is formed. It combines adsorption and oxidation in a single unit providing targeted oxidation, which means smaller footprints, lower CAPEX and lower OPEX since the energy used is proportional to the amount of organic removed. The regeneration of adsorbent in-situ and absence of any internal moving parts offers maximum uptime.
in our Frequently Asked Questions
with a sample analysis